85 Researchers have made significant advancements in understanding cervical cancer through the discovery of emerging biomarkers and molecular targets. These innovations are paving the way for precision medicine, offering the potential for improved diagnostics and personalised treatment strategies. The comprehensive study, conducted by an international team of scientists, highlights the role of biomarkers in early detection and targeted therapies, ultimately aiming to enhance patient outcomes and reduce the global burden of cervical cancer. The findings were published in the journal Biochimica et Biophysica Acta. Cervical cancer is one of the most common cancers affecting women worldwide, with approximately 604,000 new cases and 342,000 deaths reported in 2020, according to the World Health Organization (WHO). The disease primarily develops in the cervix, the lower part of the uterus, often initiated by high-risk strains of human papillomavirus (HPV). Despite advancements in screening methods such as Pap smears and HPV testing, cervical cancer remains a significant health concern, particularly in regions with limited access to healthcare resources . Precision medicine, which tailors treatment to individual patients based on their genetic and molecular profiles, has emerged as a promising approach in oncology. This study delves into the landscape of biomarkers and molecular targets in cervical cancer, highlighting their potential implications for precision medicine. By integrating these biomarkers into diagnostic algorithms, clinicians can identify high-risk patients at an earlier stage, enabling timely intervention and improved patient outcomes . Early detection of cervical cancer is crucial for effective treatment and improved survival rates. Biomarkers such as genetic mutations, protein expression patterns, and epigenetic modifications offer valuable insights into the presence and progression of cervical abnormalities. For instance, mutations in tumour suppressor genes like TP53 or oncogenes like HRAS may serve as early indicators of cervical carcinogenesis. Protein biomarkers such as p16INK4a and Ki67 have shown potential in distinguishing between normal and precancerous tissues. Additionally, DNA methylation patterns in genes like CADM1 and MAL have emerged as promising biomarkers for early-stage cervical cancer detection . Understanding the molecular pathways and genetic alterations involved in cervical cancer is essential for developing targeted therapies. The study identifies several key pathways implicated in cervical carcinogenesis, including the PI3K/Akt/mTOR pathway, the RAS/RAF/MAPK pathway, and the Wnt/β-catenin pathway. These pathways regulate various cellular processes, such as cell growth, proliferation, apoptosis, invasion, and metastasis. Dysregulation of these pathways contributes to tumour growth and progression, making them potential targets for therapeutic intervention. Recent advancements in genomic, transcriptomic, and proteomic technologies have facilitated the discovery of novel biomarkers and enhanced our understanding of cervical cancer biology. High-throughput sequencing techniques, such as whole-genome sequencing and RNA sequencing, enable comprehensive molecular profiling of cervical tumours. Proteomic techniques, including mass spectrometry and antibody-based assays, allow for the quantitative analysis of protein expression and post-translational modifications. Integrating data from these multi-omics approaches provides a holistic view of the molecular landscape of cervical cancer, aiding in the identification of robust biomarkers for early detection and personalised treatment . Targeted therapies and immunotherapies represent a significant advancement in the treatment of cervical cancer. The study highlights the potential of therapeutic vaccines targeting HPV E6 and E7 antigens, designed to induce an immune response against HPV-infected cells. Various vaccine platforms, including peptide-based, DNA, viral vector, and protein-based vaccines, are being evaluated for their efficacy in eliciting HPV-specific T-cell responses and inhibiting tumour growth. Additionally, small molecule inhibitors targeting components of crucial signaling pathways, such as PI3K inhibitors, Akt inhibitors, and mTOR inhibitors, are undergoing assessment in clinical trials . While the integration of biomarker-driven diagnostics and targeted therapies into clinical practice holds great promise, several challenges remain. Tumour heterogeneity, resistance to treatment, and limited access to molecular testing infrastructure pose significant hurdles. Overcoming these challenges requires sustained investment in translational studies, rigorous clinical validation, and the advancement of cutting-edge technologies. Moreover, fostering interdisciplinary cooperation among clinicians, researchers, industry stakeholders, and policymakers is crucial for unlocking the full potential of precision medicine in cervical cancer .